m6A: a novel strategy for osteoporosis treatment

m6A:一种治疗骨质疏松症的新策略

阅读:1

Abstract

Osteoporosis (OP) is a systemic metabolic disease characterised by increased bone fragility, with bone loss being the primary cause of its onset and progression. Regulating the dynamic balance between osteoblast (OB) formation and osteoclast-mediated bone resorption is crucial for preventing bone loss in OP. N6-methyladenosine (m6A), the most abundant and common RNA modification, is regulated by various proteins, including m6A methyltransferases, demethylases, and binding proteins. m6A methylation plays a key role in bone metabolism in OP, influencing the osteogenic and adipogenic differentiation of mesenchymal stem cells (MSCs), the osteogenic differentiation and bone formation capacity of OBs, as well as osteoclastic differentiation and resorptive activity. However, the specific molecular mechanisms through which m6A methylation regulates bone metabolism in OP remain incompletely understood. In this review, we comprehensively discuss the structure and function of m6A and summarise the roles of m6A methyltransferases, demethylases, and binding proteins. We also examine the regulatory mechanisms of m6A in MSCs, OBs, and osteoclasts, and discuss associated targeted therapies. This overview of the research on m6A is expected to highlight valuable insights and the translational potential for developing treatment strategies for OP.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。